Seroatlas · Human Serome Atlas

PBLD

Phenazine biosynthesis-like domain-containing protein

Also known as: FLJ14767, MAWBP, MAWDBP, PBLD_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P30039
Gene: PBLD
Ensembl: ENSG00000108187
Chromosome: 10
Canonical length: 288 aa
Protein class: Predicted intracellular proteins
Subcellular location: Vesicles

OverviewNCBI Gene

Enables identical protein binding activity. Involved in maintenance of gastrointestinal epithelium. Acts upstream of or within with a positive effect on negative regulation of transforming growth factor beta receptor signaling pathway. Located in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

288 residues, UniProt reviewed canonical sequence.

>P30039|PBLD
     1  MKLPIFIADA FTARAFRGNP AAVCLLENEL DEDMHQKIAR EMNLSETAFI RKLHPTDNFA
    61  QSSCFGLRWF TPASEVPLCG HATLASAAVL FHKIKNMNST LTFVTLSGEL RARRAEDGIV
   121  LDLPLYPAHP QDFHEVEDLI KTAIGNTLVQ DICYSPDTQK LLVRLSDVYN RSFLENLKVN
   181  TENLLQVENT GKVKGLILTL KGEPGGQTQA FDFYSRYFAP WVGVAEDPVT GSAHAVLSSY
   241  WSQHLGKKEM HAFQCSHRGG ELGISLRPDG RVDIRGGAAV VLEGTLTA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PBLD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.24
Highest tissue expression: 313 nTPM

Expression across tissuesHPA

Tissue

liver: 313 nTPM
kidney: 252 nTPM
duodenum: 161 nTPM
small intestine: 138 nTPM
pancreas: 59 nTPM
stomach: 52 nTPM

Single-cell type

enterocytes: 396 nCPM
hepatocytes: 271 nCPM
parietal cells: 179 nCPM
epicardial cells: 139 nCPM
epididymal efferent duct absorptive cells: 128 nCPM
cardiomyocytes: 125 nCPM

Immune cell

neutrophil: 3.3 nTPM
classical monocyte: 2.8 nTPM
myeloid DC: 2.8 nTPM
basophil: 2.5 nTPM
NK-cell: 1.8 nTPM
eosinophil: 1.5 nTPM

Brain region

white matter: 30 nTPM
cerebellum: 24 nTPM
basal ganglia: 24 nTPM
cerebral cortex: 24 nTPM
medulla oblongata: 23 nTPM
hypothalamus: 22 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.57
gnomAD pLI: 0
gnomAD missense Z: 0.35
DepMap mean gene effect: 0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

Phenazine biosynthesis PhzF-like
Phenazine biosynthesis-like protein

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PBLD in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PBLD as an antibody target. Whether an autoantibody or antibody against PBLD could matter depends on whether native PBLD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PBLD is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PBLD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...